Trial Profile
Open Label Study to Evaluate Product Design Clinical Performance of a To-Be-Marketed Drug-Device Combination Product (sc2Wear Furosemide Combination Product) in Subjects With Chronic Heart Failure
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 Oct 2017
Price :
$35
*
At a glance
- Drugs Furosemide (Primary)
- Indications Cardiac oedema; Chronic heart failure
- Focus Registrational; Therapeutic Use
- Sponsors scPharmaceuticals
- 16 Feb 2017 Status changed from not yet recruiting to completed.
- 22 Jun 2016 New trial record